PCRX vs CRON

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 24, 2026

PCRX

58.6
AI Score
VS
PCRX Wins

CRON

33.3
AI Score

Investment Advisor Scores

PCRX

59score
Recommendation
STRONG BUY

CRON

33score
Recommendation
SELL

AI Analyst Insights

Detailed Metrics Comparison

Metric PCRX CRON Winner
Forward P/E 8.726 19.7628 PCRX
PEG Ratio 11.2121 0 Tie
Revenue Growth 6.2% 58.4% CRON
Earnings Growth -30.0% 126.8% CRON
Tradestie Score 58.6/100 33.3/100 PCRX
Profit Margin 2.0% 39.1% CRON
Beta 1.00 1.00 Tie
AI Recommendation STRONG BUY SELL PCRX

Relative Price Performance (Last 90 Days)

PCRX 1M: -4.9% · 3M: +5.1% CRON 1M: +20.8% · 3M: +21.2%

Current Technical Phase

PCRX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 49.5 · Price: $24.67

CRON

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (4.3% over 20 days), RSI 69

RSI (14): 69.3 · Price: $3.31

Fundamentals Snapshot

Metric PCRX CRON
Market Cap
Forward P/E 6.9 20.9
Trailing P/E 67.7 16.9
Revenue (TTM)
Revenue Growth 0.1% 0.6%
Gross Margin 0.8% 0.4%
Operating Margin 0.1% 0.2%
EPS 0.36 0.19
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, PCRX is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.